Biodistribution studies have been performed for an anti-CEA targeted monoclonal antibody labeled to a 700-nm fluorophore, SGM-101, although only using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging, making a fair comparison of our results to their tumor to organ ratios difficult, however, tracer accumulation in the kidneys seemed to be much higher for the monoclonal antibody compared to the Nanobody [27]. The gene discussed is CEACAM5; the disease is neoplasm.